Faron Pharmaceuticals: Positive FDA feedback - Redeye

Redeye leaves a note following Faron’s announcement of positive feedback from its meeting with the FDA ahead of phase III trials. We believe that the FDA's new proposal potentially reduces development costs and time-to-market while also broadening bexmarilimab’s label to all HR MDS patients.

Länk till analysen i sin helhet: https://www.redeye.se/research/1021159/faron-pharmaceuticals-positive-fda-feedback?utm_source=finwire&utm_medium=RSS